The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

The blood test, branded as Lumipulse, will initially likely be used to rule out Alzheimer's, with positive results signaling the need for more advanced diagnostics. Alzheimer's, which gradually ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately ...